On Monday, Shares of Ford Motor Co. (NYSE:F), lost -4.83% to $13.19, hitting its lowest level.
Ford Motor Company declared its popular high school fundraising program – Drive 4 UR School – will collaborate with the rock band Foreigner to create and host special choir fundraisers in select states. The initiative, Rock Then Roll 4 UR School, will take place in tandem with Foreigner concerts this October.
“We are delighted to partner with such an iconic and influential band like Foreigner to provide support and visibility for high school choir programs,” said Tracy Magee, Ford experiential marketing manager. “Rock Then Roll 4 UR School is a unique iteration of our popular Drive 4 UR School and Drive 4 UR Community fundraising programs, and we’re hopeful it will inspire local communities to support students and their passion for music.”
Ford Motor Company manufactures and distributes automobiles worldwide. The company operates through two sectors, Automotive and Financial Services. The Automotive sector develops, manufactures, distributes, and services vehicles, parts, and accessories.
Shares of AbbVie Inc. (NYSE:ABBV), declined -3.72% to $63.45, during its last trading session.
United Therapeutics Corporation (UTHR) declared that it has reached a contract to sell its Rare Pediatric Disease Precedingity Review Voucher (PPRV) to a partner of AbbVie Inc. (ABBV). United Therapeutics received the PPRV when Unituxin™ was approved by the U.S. Food and Drug Administration (FDA) for the treatment of neuroblastoma, a rare pediatric disease.
Upon closing of the transaction, United Therapeutics will receive $350 million in cash in exchange for the PPRV. The voucher was awarded by the FDA under a provision that encourages development of new drugs and biologics for the prevention and treatment of rare pediatric diseases.
The transaction is subject to customary closing conditions and clearance under the Hart-Scott-Rodino Antitrust Improvements Act.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company’s products comprise HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; VIEKIRA PAK, an all-oral, short-course, interferon-free therapy, with or without ribavirin, for adult patients with genotype 1 chronic hepatitis, counting those with compensated cirrhosis; Kaletra, an anti-HIV-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1 infection; and Synagis to prevent respiratory syncytial virus infection in high risk infants.
Finally, Occidental Petroleum Corporation (NYSE:OXY), ended its last trade with -5.10% loss, and closed at $65.73, as Oil prices plunged to fresh six-year lows Monday on concerns about a slowdown in Chinese demand and growing crude-oil supplies in the U.S., according to WSJ.
Brent, the global oil benchmark, fell through its January lows to trade below $45 a barrel for the first time in six years. Brent settled down $2.77, or 6.1%, at $42.69 a barrel on ICE Futures Europe, the lowest settlement since March 2009. WSJ Reports
The U.S. oil benchmark settled down $2.21, or 5.5%, at $38.24 a barrel on the New York Mercantile Exchange, the first settlement below $40 a barrel since February 2009. WSJ added.
Occidental Petroleum Corporation engages in the acquisition, exploration, and development of oil and gas properties in the United States and internationally. The company operates in three segments: Oil and Gas; Chemical; and Midstream, Marketing and Other.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
